These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 38582965)
1. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Ahn T; Bae EA; Seo H Mol Ther; 2024 Jun; 32(6):1617-1627. PubMed ID: 38582965 [TBL] [Abstract][Full Text] [Related]
2. T-cell exhaustion in multiple myeloma. Żyłka K; Kubicki T; Gil L; Dytfeld D Expert Rev Hematol; 2024 Jul; 17(7):295-312. PubMed ID: 38919090 [TBL] [Abstract][Full Text] [Related]
4. Engineering chimeric antigen receptor-T cells for cancer treatment. Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937 [TBL] [Abstract][Full Text] [Related]
6. Epigenetic reprogramming of CAR T cells for in vivo functional persistence against solid tumors. Saitakis M Genes Immun; 2024 Oct; 25(5):434-436. PubMed ID: 38388813 [TBL] [Abstract][Full Text] [Related]
7. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
8. Exhausted T cells and epigenetic status. Zeng Z; Wei F; Ren X Cancer Biol Med; 2020 Nov; 17(4):923-936. PubMed ID: 33299644 [TBL] [Abstract][Full Text] [Related]
9. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties. Nunoya JI; Imuta N; Masuda M Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201348 [TBL] [Abstract][Full Text] [Related]
12. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987 [TBL] [Abstract][Full Text] [Related]
13. T cell exhaustion in human cancers. Kang K; Lin X; Chen P; Liu H; Liu F; Xiong W; Li G; Yi M; Li X; Wang H; Xiang B Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189162. PubMed ID: 39089484 [TBL] [Abstract][Full Text] [Related]
14. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Jain N; Zhao Z; Feucht J; Koche R; Iyer A; Dobrin A; Mansilla-Soto J; Yang J; Zhan Y; Lopez M; Gunset G; Sadelain M Nature; 2023 Mar; 615(7951):315-322. PubMed ID: 36755094 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic engineering for optimal chimeric antigen receptor T cell therapy. Ito Y; Kagoya Y Cancer Sci; 2022 Nov; 113(11):3664-3671. PubMed ID: 36000807 [TBL] [Abstract][Full Text] [Related]
17. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289 [TBL] [Abstract][Full Text] [Related]
18. Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility. Giorgioni L; Ambrosone A; Cometa MF; Salvati AL; Nisticò R; Magrelli A Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408696 [TBL] [Abstract][Full Text] [Related]
19. Transcription factors in chimeric antigen receptor T-cell development. Dai A; Zhang X; Wang X; Liu G; Wang Q; Yu F Hum Cell; 2024 May; 37(3):571-581. PubMed ID: 38436882 [TBL] [Abstract][Full Text] [Related]